Cargando…

Posterior Reversible Encephalopathy Syndrome

PURPOSE OF REVIEW: This review provides an updated discussion on the clinical presentation, diagnosis and radiographic features, mechanisms, associations and epidemiology, treatment, and prognosis of posterior reversible encephalopathy syndrome (PRES). Headache is common in PRES, though headache ass...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gewirtz, Alexandra N., Gao, Virginia, Parauda, Sarah C., Robbins, Matthew S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Secondary Headache (M Robbins, Section Editor)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905767/ https://www.ncbi.nlm.nih.gov/pubmed/33630183 http://dx.doi.org/10.1007/s11916-020-00932-1

Ejemplares similares

Cognitive Impairment in Primary and Secondary Headache Disorders
por: Begasse de Dhaem, Olivia, et al.
Publicado: (2022)

Headache After Vaccination: An Update on Recent Clinical Trials and Real-World Reporting
por: Garces, Kimberly N., et al.
Publicado: (2022)

Symptomatic Trigeminal Autonomic Cephalalgias
por: de Coo, Ilse F., et al.
Publicado: (2015)

Posterior reversible encephalopathy syndrome in patients with COVID-19
por: Parauda, Sarah C., et al.
Publicado: (2020)

Current Understanding of What Infants See
por: Hyvärinen, Lea, et al.
Publicado: (2014)

Clinic and genetic predictors in response to erenumab
por: Zecca, Chiara, et al.
Publicado: (2022)

Treatment with the monoclonal calcitonin gene‐related peptide receptor antibody erenumab: A real‐life study
por: de Vries Lentsch, Simone, et al.
Publicado: (2021)

Cold extremities in migraine: a marker for vascular dysfunction in women
por: Linstra, K. M., et al.
Publicado: (2020)

Headache as an acute and post‐COVID‐19 symptom in COVID‐19 survivors: A meta‐analysis of the current literature
por: Fernández‐de‐las‐Peñas, César, et al.
Publicado: (2021)

Chronic migraine: Genetics or environment?
por: Chalmer, Mona Ameri, et al.
Publicado: (2021)

Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial
por: Ashina, Messoud, et al.
Publicado: (2021)

Multinational descriptive analysis of the real‐world burden of headache using the Migraine Buddy application
por: Goadsby, Peter J., et al.
Publicado: (2021)

Functional connectivity changes in complex migraine aura: beyond the visual network
por: Silvestro, Marcello, et al.
Publicado: (2021)

Acute Migraine Therapy: New Drugs and New Approaches
por: Monteith, Teshamae S., et al.
Publicado: (2010)

Headaches and obesity
por: Fortini, Ida, et al.
Publicado: (2022)

Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
por: Simioni, Caio Vinicius de Meira Grava
Publicado: (2022)

Update on Idiopathic Intracranial Hypertension Management
por: Souza, Marcio Nattan Portes, et al.
Publicado: (2022)

Vestibular migraine
por: Silva, Viviane Passarelli Ramin, et al.
Publicado: (2022)

It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
por: Kubota, Gabriel Taricani
Publicado: (2022)

Erenumab in chronic migraine: Experience from a UK tertiary centre and comparison with other real‐world evidence
por: Khalil, Modar, et al.
Publicado: (2022)

First‐line steroid treatment for spontaneous intracranial hypotension
por: Tonello, Simone, et al.
Publicado: (2022)

Behavioural intervention in medication overuse headache: A concealed double‐blind randomized controlled trial
por: Pijpers, Judith A., et al.
Publicado: (2022)

Maintenance of response and predictive factors of 1‐year GalcanezumAb treatment in real‐life migraine patients in Italy: The multicenter prospective cohort GARLIT study
por: Vernieri, Fabrizio, et al.
Publicado: (2022)

Long‐term risk of seizure after posterior reversible encephalopathy syndrome
por: Seitz, Alison, et al.
Publicado: (2023)

Malignant Posterior Reversible Encephalopathy Syndrome: A Case of Posterior Irreversible Encephalopathy Syndrome
por: Martins, William Alves, et al.
Publicado: (2016)

Effect of l-phenylalanine on PAL activity and production of naphthoquinone pigments in suspension cultures of Arnebia euchroma (Royle) Johnst
por: Sykłowska-Baranek, Katarzyna, et al.
Publicado: (2012)

The impact of media composition on production of flavonoids in agitated shoot cultures of the three Hypericum perforatum L. cultivars ‘Elixir,’ ‘Helos,’ and ‘Topas’
por: Kwiecień, Inga, et al.
Publicado: (2018)

Hypertension, headache, and posterior reversible encephalopathy syndrome
por: Mohammed, Hassan
Publicado: (2016)

Hyperthermia inducing posterior reversible encephalopathy syndrome
por: Yassin, Ahmed, et al.
Publicado: (2020)

The History of the Migraine Trust
por: Rose, F. C.
Publicado: (2006)

Acute Intermittent Porphyria and Posterior Reversible Encephalopathy Syndrome
por: Abdulla, Mansoor C
Publicado: (2020)

Reversible Cerebral Vasoconstriction Syndrome after Nifedipine Withdrawal
por: Alanazy, Mohammed H., et al.
Publicado: (2020)

Concepts leading to the definition of the term cervicogenic headache: a historical overview
por: Antonaci, F., et al.
Publicado: (2005)

Chronic paroxysmal hemicrania, hemicrania continua and SUNCT: the fate of the three first described cases
por: Sjaastad, Ottar
Publicado: (2006)

Introduction to the History of Headache Section
Publicado: (2004)

Headache among the educated in the century of enlightment
por: Zanchin, Giorgio, et al.
Publicado: (2004)

The nervous system in colours: the tabulae pictae of G.F. d’Acquapendente (ca. 1533–1619)
por: Zanchin, G., et al.
Publicado: (2006)

Sources
por: Zanchin, Giorgio
Publicado: (2004)

New additions to the History of Headache Section
por: Zanchin, Giorgio
Publicado: (2004)

Posterior reversible encephalopathy syndrome in minimal change disease
por: Swarnalatha, G., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_s47f2bpr5a6gn02e3pids7f0o4